Fig. 3: Association of checkpoint types with DFS. | Cancer Gene Therapy

Fig. 3: Association of checkpoint types with DFS.

From: Siglec-15 on macrophages suppress the immune microenvironment in patients with PD-L1 negative non-metastasis lung adenocarcinoma

Fig. 3

A Representative images of LUAD tissue sections with checkpoint type I (Siglec-15 positivity with PD-L1 positivity), type II (Siglec-15 positivity with PD-L1 negativity), type III (Siglec-15 negativity with PD-L1 positivity), and type IV (Siglec-15 negativity with PD-L1 negativity). Scale bar, 50 μm. B Chi-Square test showed the relationship between Siglec-15 and PD-L1 patterns. C Comparison of DFS by different types in non-metastasis LUAD patients. D, E Chi-Square test showed the relationship between Mφ-Siglec-15 and TC-PD-L1/NTC-PD-L1. F, G Comparison of DFS among Mφ-Siglec-15 and TC-PD-L1/NTC-PD-L1 patterns in non-metastasis LUAD patients.

Back to article page